AU2018270092B2 - Methods of treatment for cervical dystonia - Google Patents

Methods of treatment for cervical dystonia Download PDF

Info

Publication number
AU2018270092B2
AU2018270092B2 AU2018270092A AU2018270092A AU2018270092B2 AU 2018270092 B2 AU2018270092 B2 AU 2018270092B2 AU 2018270092 A AU2018270092 A AU 2018270092A AU 2018270092 A AU2018270092 A AU 2018270092A AU 2018270092 B2 AU2018270092 B2 AU 2018270092B2
Authority
AU
Australia
Prior art keywords
botulinum toxin
treatment
months
duration
individual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018270092A
Other languages
English (en)
Other versions
AU2018270092A1 (en
Inventor
Curtis L. Ruegg
Jacob M. Waugh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Revance Therapeuticals Inc
Original Assignee
Revance Therapeuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Revance Therapeuticals Inc filed Critical Revance Therapeuticals Inc
Publication of AU2018270092A1 publication Critical patent/AU2018270092A1/en
Application granted granted Critical
Publication of AU2018270092B2 publication Critical patent/AU2018270092B2/en
Priority to AU2025205532A priority Critical patent/AU2025205532A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
AU2018270092A 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia Active AU2018270092B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2025205532A AU2025205532A1 (en) 2017-05-18 2025-07-16 Methods of treatment for cervical dystonia

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762508324P 2017-05-18 2017-05-18
US62/508,324 2017-05-18
PCT/US2018/033397 WO2018213710A1 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2025205532A Division AU2025205532A1 (en) 2017-05-18 2025-07-16 Methods of treatment for cervical dystonia

Publications (2)

Publication Number Publication Date
AU2018270092A1 AU2018270092A1 (en) 2019-12-19
AU2018270092B2 true AU2018270092B2 (en) 2025-04-17

Family

ID=64274745

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2018270092A Active AU2018270092B2 (en) 2017-05-18 2018-05-18 Methods of treatment for cervical dystonia
AU2025205532A Pending AU2025205532A1 (en) 2017-05-18 2025-07-16 Methods of treatment for cervical dystonia

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2025205532A Pending AU2025205532A1 (en) 2017-05-18 2025-07-16 Methods of treatment for cervical dystonia

Country Status (13)

Country Link
US (3) US20200179498A1 (enExample)
EP (1) EP3624819A4 (enExample)
JP (1) JP2020520917A (enExample)
KR (2) KR20250037595A (enExample)
CN (1) CN110996979A (enExample)
AU (2) AU2018270092B2 (enExample)
BR (1) BR112019024082A2 (enExample)
CA (1) CA3064070A1 (enExample)
CO (1) CO2019014212A2 (enExample)
MX (1) MX2019013716A (enExample)
PH (1) PH12019502578A1 (enExample)
RU (1) RU2019141383A (enExample)
WO (1) WO2018213710A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2490986T3 (pl) * 2009-10-21 2019-03-29 Revance Therapeutics, Inc. Sposoby i systemy oczyszczania nieskompleksowanej neurotoksyny botulinowej
US12161703B2 (en) 2017-08-28 2024-12-10 Revance Therapeutics, Inc. Transmucosal botulinum toxin compositions, kits, and methods for treating bladder disorders
EP4228599A4 (en) * 2020-10-13 2025-03-12 ReVance Therapeutics, Inc. METHODS FOR TREATMENT OF CERVICAL DYSTONIA
AU2022223782A1 (en) * 2021-02-21 2023-09-21 Revance Therapeutics, Inc. Methods of and compositions for treatment of upper limb spasticity
WO2025059665A1 (en) 2023-09-15 2025-03-20 Revance Therapeutics, Inc. Serial treatment with botulinum toxin for cervical dystonia

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100168023A1 (en) * 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
EP2985039A1 (en) * 2004-03-03 2016-02-17 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
WO2017075468A1 (en) * 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8557256B2 (en) * 1993-12-28 2013-10-15 Allergan, Inc. Treatment for cervical dystonia with the neurotoxic component of a botulinum toxin
TW574036B (en) * 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
BRPI1015938A2 (pt) * 2009-06-25 2016-09-27 Revance Therapeutics Inc formulações da toxina botulínica livre de albumina
US8147848B2 (en) * 2009-08-26 2012-04-03 Allergan, Inc. Method for treating premature ejaculation with a botulinum neurotoxin
HRP20171483T1 (hr) * 2011-01-07 2017-12-01 Revance Therapeutics, Inc. Topikalni pripravak koji se sastoji od botulinskog toksina i boje
AU2012283968B2 (en) * 2011-07-20 2016-04-14 Allergan, Inc. Botulinum toxins for use in a method for treatment of adipose deposits
WO2019090257A1 (en) * 2017-11-03 2019-05-09 Revance Therapeutics, Inc. Botulinum toxin formulations and methods of use thereof in plantar fasciitis with extended duration of effect
MX2020005785A (es) * 2017-12-04 2020-10-28 Revance Therapeutics Inc Formulaciones inyectables de toxina botulínica y métodos de uso de las mismas que tienen una alta tasa de respuesta y una larga duración del efecto.
RU2741221C1 (ru) 2020-04-30 2021-01-22 Федеральное государственное автономное образовательное учреждение высшего образования "Крымский федеральный университет имени В.И. Вернадского" (ФГАОУ ВО "КФУ им. В.И. Вернадского") Способ комплексной реабилитации двигательной функции верхней конечности у больных детским церебральным параличом

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2985039A1 (en) * 2004-03-03 2016-02-17 ReVance Therapeutics, Inc. Topical application and transdermal delivery of botulinum toxins
US20100168023A1 (en) * 2008-12-31 2010-07-01 Revance Therapeutics, Inc. Injectable Botulinum Toxin Formulations
WO2017075468A1 (en) * 2015-10-29 2017-05-04 Revance Therapeutics, Inc. Injectable botulinum toxin formulations and methods of use thereof having long duration of therapeutic or cosmetic effect

Also Published As

Publication number Publication date
US20200179498A1 (en) 2020-06-11
JP2020520917A (ja) 2020-07-16
KR20200006587A (ko) 2020-01-20
RU2019141383A (ru) 2021-06-18
KR102777928B1 (ko) 2025-03-10
RU2019141383A3 (enExample) 2022-01-19
US20250319168A1 (en) 2025-10-16
CA3064070A1 (en) 2018-11-22
BR112019024082A2 (pt) 2020-06-16
NZ759612A (en) 2024-01-26
US12257293B2 (en) 2025-03-25
US20220096610A1 (en) 2022-03-31
CO2019014212A2 (es) 2020-01-17
PH12019502578A1 (en) 2020-07-20
MX2019013716A (es) 2020-10-12
EP3624819A1 (en) 2020-03-25
CN110996979A (zh) 2020-04-10
EP3624819A4 (en) 2021-03-24
AU2018270092A1 (en) 2019-12-19
WO2018213710A1 (en) 2018-11-22
AU2025205532A1 (en) 2025-08-07
KR20250037595A (ko) 2025-03-17

Similar Documents

Publication Publication Date Title
US12257293B2 (en) Methods of treatment for cervical dystonia
JP6559849B2 (ja) 注射用ボツリヌス毒素製剤
EP2413947B1 (en) Methods and compositions for treating skin conditions associated with vascular hyper-reactivity
US20240269246A1 (en) Methods for treating cervical dystonia
WO2025059665A1 (en) Serial treatment with botulinum toxin for cervical dystonia
US20250268996A1 (en) Methods of and compositions for treatment of upper limb spasticity
HK40020585A (en) Methods of treatment for cervical dystonia
HK1240854A1 (en) Injectable botulinum toxin formulations
HK1162925A (en) Injectable botulinum toxin formulations

Legal Events

Date Code Title Description
DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 APR 2025

TH Corrigenda

Free format text: IN VOL 59 , NO 26 , PAGE(S) 3667 UNDER THE HEADING AMENDMENTS - APPLICATION FOR AMENDMENTS UNDER THE NAME REVANCE THERAPEUTICS, INC., PATENT APPLICATION NO. 2018270092 CORRECT THE DATE OF THE STATEMENTS FILED TO READ 08 APR 2025, 30 MAY 2025 AND 6 JUN 2025